An open-label multicentre long-term extension study of etanercept in ankylosing spondylitis

Trial Profile

An open-label multicentre long-term extension study of etanercept in ankylosing spondylitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2010

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 01 Jun 2010 Results for up to 5 years of open-label extension treatment have been reported in Clinical and Experimental Rheumatology 2010; 28: 238-245.
    • 27 Aug 2007 Status changed from in progress to completed.
    • 28 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top